ConductScience.org, home
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
API referenceFor AI assistants

Trial · NCT00436618

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 12 of 12

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Tumor Response, Defined by Disease: Chronic Lymphocytic Leukemia(CLL): Clinical Complete or Complete or Nodular Partial or Partial Remission, Waldenstrom: Complete or Partial Response, All Others: Complete or Complete Unconfirmed or Partial Response.
Relapsed Aggressive Non-Hodgkin Lymphoma2695% Confidence Interval 19 to 35percentage of patients in group
Tumor Response, Defined by Disease: Chronic Lymphocytic Leukemia(CLL): Clinical Complete or Complete or Nodular Partial or Partial Remission, Waldenstrom: Complete or Partial Response, All Others: Complete or Complete Unconfirmed or Partial Response.
Relapsed Indolent Non-Hodgkin Lymphoma3595% Confidence Interval 22 to 49percentage of patients in group
Tumor Response, Defined by Disease: Chronic Lymphocytic Leukemia(CLL): Clinical Complete or Complete or Nodular Partial or Partial Remission, Waldenstrom: Complete or Partial Response, All Others: Complete or Complete Unconfirmed or Partial Response.
Uncommon Lymphomas4995% Confidence Interval 39 to 58percentage of patients in group
Overall SurvivalRelapsed Aggressive Non-Hodgkin Lymphoma0.6695% Confidence Interval 0.44 to 0.99years
Overall SurvivalRelapsed Indolent Non-Hodgkin Lymphoma2.4595% Confidence Interval 1.04 to 4.97years
Overall SurvivalUncommon Lymphomas3.4195% Confidence Interval 2.31 to 5.13years
Progression-free SurvivalRelapsed Aggressive Non-Hodgkin Lymphoma0.1895% Confidence Interval 0.16 to 0.27years
Progression-free SurvivalRelapsed Indolent Non-Hodgkin Lymphoma0.6095% Confidence Interval 0.41 to 1.03years
Progression-free SurvivalUncommon Lymphomas0.7995% Confidence Interval 0.52 to 1.09years
Time to ProgressionRelapsed Aggressive Non-Hodgkin Lymphoma0.1895% Confidence Interval 0.16 to 0.29years
Time to ProgressionRelapsed Indolent Non-Hodgkin Lymphoma0.6095% Confidence Interval 0.42 to 1.16years
Time to ProgressionUncommon Lymphomas0.9095% Confidence Interval 0.62 to 1.49years

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00436618/results

API referenceFor AI assistants